Denileukin Diftitox as Prophylaxis against Graft-versus-Host Disease in the Canine Hematopoietic Cell Transplantation Model

Marco Mielcarek*, George E. Georges, Rainer Storb

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Denileukin diftitox (Ontak) was evaluated in combination with methotrexate (MTX) for preventing acute graft-versus-host disease (GVHD) in dogs given 9.2 Gy of total body irradiation and DLA-nonidentical hematopoietic cell grafts. Six dogs were given denileukin diftitox 9 μg/kg/day intravenously (IV) on days 2, 4, 5, 7, 8, and 10, in combination with MTX 0.4 mg/kg/day IV on days 1, 3, 6, and 11 after transplantation. Median survival of the dogs given MTX in combination with denileukin diftitox was 16 days (range, 13-18 days), similar to that of 35 historical controls given MTX alone (median survival, 20 days). Five of the 6 denileukin diftitox-treated dogs had clinical and pathological evidence of 3-system GVHD; 1 dog died of canine herpes virus infection without evidence of GVHD. In conclusion, denileukin diftitox did not prevent, mitigate, or delay acute GVHD in this stringent and predictive (with respect to outcomes in human patients) hematopoietic cell transplantation model.

Original languageEnglish (US)
Pages (from-to)899-904
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume12
Issue number9
DOIs
StatePublished - Sep 2006

Keywords

  • Hematopoietic cell transplantation
  • canine model
  • denileukin diftitox
  • graft-versus-host disease

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Fingerprint

Dive into the research topics of 'Denileukin Diftitox as Prophylaxis against Graft-versus-Host Disease in the Canine Hematopoietic Cell Transplantation Model'. Together they form a unique fingerprint.

Cite this